Lite Strategy/$LITS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Lite Strategy
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients. The company operates in the segments: Digital Asset Treasury Strategy and Development of Pharmaceutical Products.
- Ticker
- $LITS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 5
- Headquarters
- San Diego, United States
- Website
- www.litestrategy.com
Lite Strategy Metrics
BasicAdvanced
$30M
-
-$1.46
-
-
Price and volume
Market cap
$30M
52-week high
$2.15
52-week low
$0.69
Average daily volume
372K
Financial strength
Current ratio
3.636
Quick ratio
2.509
Profitability
Management effectiveness
Return on assets (TTM)
-8.25%
Return on equity (TTM)
-60.95%
Valuation
Price to book
0.52
Price to tangible book (TTM)
0.52
Price to free cash flow (TTM)
-5.149
Free cash flow yield (TTM)
-19.42%
Free cash flow per share (TTM)
-0.191
Growth
Earnings per share change (TTM)
55.60%
3-year earnings per share growth (CAGR)
-38.20%
10-year earnings per share growth (CAGR)
-18.94%
Lite Strategy Financial Performance
Revenues and expenses
Lite Strategy Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.